文献速递主动脉疾病

GLP-1受体激动剂与腹主动脉瘤相关事件风险降低相关

Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events.
PubMed 文献 · J Vasc Surg · 2025-11-21

本研究基于TriNetX美国协作网络,纳入2015至2020年未破裂腹主动脉瘤患者,按2型糖尿病状态分层,倾向性评分匹配后分析GLP-1RA使用与全因死亡、AAA修复及急性主动脉综合征的关联。结果显示GLP-1RA使用者在合并及不合并2型糖尿病队列中复合结局风险均显著降低。

要点

  • GLP-1RA使用与未破裂AAA患者复合结局风险降低相关(T2D OR 0.56;非T2D OR 0.42)。
  • GLP-1RA使用者全因死亡和AAA修复风险均降低。
  • 需进一步研究GLP-1RA对动脉瘤生长和进展的影响。

核心结论

  • GLP-1RA处方与未破裂腹主动脉瘤患者临床重要事件风险降低相关。

研究设计与样本

  • 基于TriNetX美国协作网络,识别2015年1月1日至2020年3月1日ICD-10编码的≥18岁未破裂AAA患者,排除既往AAA破裂、夹层、修复及结缔组织病患者。
  • 按2型糖尿病状态分层,分为研究期间首次AAA诊断前6个月内或之后任何时间有GLP-1RA处方者与从未处方GLP-1RA者,进行1:1倾向性评分匹配调整人口学、吸烟、合并症和药物。
  • 合并T2D队列中GLP-1RA组1407例、非GLP-1RA组38994例,匹配后各1401例分析;非T2D队列中GLP-1RA组336例、非GLP-1RA组129790例,匹配后336对分析。

主要发现

  • 合并T2D队列中,GLP-1RA组复合结局(死亡、AAA修复、急性腹主动脉综合征)OR为0.56(95%CI 0.47-0.66)。
  • 非T2D队列中,GLP-1RA组复合结局OR为0.42(95%CI 0.28-0.63)。
  • 合并T2D队列中,GLP-1RA组死亡OR为0.54(95%CI 0.45-0.65),AAA修复OR为0.66(95%CI 0.45-0.95)。
  • 非T2D队列中,GLP-1RA组死亡OR为0.47(95%CI 0.30-0.74),AAA修复OR为0.45(95%CI 0.21-0.96)。
  • Kaplan-Meier分析显示GLP-1RA延缓结局发生。

临床怎么用

  • 在未破裂AAA患者中,尤其合并T2D者,GLP-1RA的使用可能与降低死亡和AAA修复风险相关,可考虑作为综合管理的一部分。
  • 非T2D的AAA患者使用GLP-1RA也可能获益,但需个体化评估。

局限性

  • 本研究为回顾性队列研究,存在未测量混杂可能。
  • GLP-1RA对动脉瘤生长和进展的影响尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown to possess cardiovascular protective effects, with preclinical data, suggesting potential benefits in slowing abdominal aortic aneurysm (AAA) growth. However, their effect on AAA in humans remains underexplored. This study evaluates the effects of GLP-1RAs on all-cause mortality, AAA repair, and acute abdominal aortic syndrome in patients with unruptured AAA. METHODS: We used the US collaborative network of the TriNetX platform to identify patients aged ≥18 years with unruptured AAA, based on International Classification of Disease, 10th Revision (ICD-10), codes from January 1, 2015, to March 1, 2020. Patients with prior AAA rupture, dissection, repair, and connective tissue disorders were excluded. The remaining cohort was stratified by type 2 diabetes (T2D) status and divided into two cohorts: patients who had GLP-1RA prescription within 6 months before or any time after their first AAA encounter diagnosis during the study period and non-GLP-1RA users who were never prescribed GLP-1RAs. Propensity score matching (1:1) adjusted for demographics, tobacco use, comorbidities, and medications. Five-year odds ratios (ORs) and Kaplan-Meier survival analyses assessed outcomes. RESULTS: Of the 1407 patients prescribed GLP-1RAs and 38,994 not prescribed GLP-1RAs with T2D, 1401 patients were matched and analyzed. Similarly, among 336 patient prescribed GLP-1RAs and 129,790 not prescribed non-GLP-1RAs without T2D, 336 matched pairs were analyzed. Patient prescribed GLP-1RAs had significantly lower risks of the composite outcome of mortality, AAA repair, and acute abdominal aortic syndrome in both T2D (OR, 0.56; 95% confidence interval [CI], 0.47-0.66) and non-T2D cohorts (OR, 0.42; 95% CI, 0.28-0.63). Specifically, those prescribed GLP-1RAs had reduced mortality (T2D: OR, 0.54; 95% CI, 0.45-0.65; non-T2D: OR, 0.47; 95% CI, 0.30-0.74) and were less likely to undergo AAA repair (T2D: OR, 0.66; 95% CI, 0.45-0.95; non-T2D: OR, 0.45; 95% CI, 0.21-0.96). Kaplan-Meier analysis also demonstrated the benefits of GLP-1RAs in delaying outcome. CONCLUSIONS: GLP-1RA prescriptions were associated with a lower risk of clinically important events in patients with unruptured AAA. These findings suggest potential benefits of GLP-1RAs in AAA management, warranting further research on their effect on aneurysm growth and progression.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ahn H, Kaelber DC, Hoell N, et al. Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events. J Vasc Surg. 2025. PMID: 41276093. doi:10.1016/j.jvs.2025.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。